STOCK TITAN

[8-K] OPKO HEALTH, INC. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

OPKO Health (OPK) furnished an 8-K stating it issued a press release with operating and financial highlights for the quarter ended September 30, 2025. The release also explains how to access the company’s conference call covering third-quarter results and provides financial guidance. The information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, and a copy of the press release is attached as Exhibit 99.1.

OPKO Health (OPK) ha fornito un 8-K dichiarando di aver emesso un comunicato stampa con evidenze operative e finanziarie per il trimestre conclusosi il 30 settembre 2025. Il comunicato spiega anche come accedere alla conferenza telefonica dell’azienda che copre i risultati del terzo trimestre e fornisce le previsioni finanziarie. Le informazioni in Item 2.02 e nell'Esibizione 99.1 sono fornite, non depositate, e una copia del comunicato stampa è allegata come Esibizione 99.1.

OPKO Health (OPK) presentó un 8-K indicando que emitió un comunicado de prensa con los aspectos operativos y financieros para el trimestre terminado al 30 de septiembre de 2025. El comunicado también explica cómo acceder a la llamada de conferencia de la empresa que cubre los resultados del tercer trimestre y proporciona orientación financiera. La información en el Item 2.02 y en el Anexo 99.1 se está proporcionando, no presentado, y se adjunta una copia del comunicado de prensa como Anexo 99.1.

OPKO Health (OPK)가 8-K를 제출했습니다 분기말 2025년 9월 30일에 대한 운영 및 재무 하이라이트가 담긴 보도자료를 발행했다고 명시했습니다. 또한 보도자료는 회사의 3분기 실적 발표 컨퍼런스 콜에 접속하는 방법과 재무 전망에 대해 설명합니다. Item 2.02 및 Exhibit 99.1의 정보는 제출되는 것이지 기재되는 것이 아니며, 보도자료의 사본은 Exhibit 99.1로 첨부되어 있습니다.

OPKO Health (OPK) a fourni un formulaire 8-K indiquant qu'il a publié un communiqué de presse présentant les points saillants opérationnels et financiers pour le trimestre se terminant le 30 septembre 2025. Le communiqué explique également comment accéder à la conférence téléphonique de l'entreprise couvrant les résultats du troisième trimestre et fournit des prévisions financières. Les informations contenues dans l'Item 2.02 et l'Exhibit 99.1 sont fournies, et non déposées, et une copie du communiqué de presse est jointe en tant qu'Exhibit 99.1.

OPKO Health (OPK) hat eine 8-K vorgelegt, in der mitgeteilt wird, dass ein Pressemitteilung mit operativen und finanziellen Highlights für das Quartal zum 30. September 2025 veröffentlicht wurde. Die Mitteilung erläutert auch, wie man die Telefonkonferenz des Unternehmens zu den Ergebnissen des dritten Quartals zugänglich macht, und gibt finanzielle Leitlinien an. Die Informationen in Item 2.02 und Exhibit 99.1 werden als vorgelegt, nicht eingereicht, und eine Kopie der Pressemitteilung ist als Exhibit 99.1 beigefügt.

قدمت OPKO Health (OPK) نموذج 8-K تفيد أنها أصدرت بياناً صحفياً يبرز النقاط التشغيلية والمالية للربع المنتهي في 30 سبتمبر 2025. كما يشرح البيان كيفية الوصول إلى مكالمة المؤتمر الخاصة بالشركة التي تغطي نتائج الربع الثالث ويقدم توجيهات مالية. المعلومات الواردة في البند 2.02 والمعرض 99.1 يتم تقديمها، وليست مُقدمة للتسجيل، ونُسخة من البيان الصحفي مرفقة كالمعرض 99.1.

Positive
  • None.
Negative
  • None.

OPKO Health (OPK) ha fornito un 8-K dichiarando di aver emesso un comunicato stampa con evidenze operative e finanziarie per il trimestre conclusosi il 30 settembre 2025. Il comunicato spiega anche come accedere alla conferenza telefonica dell’azienda che copre i risultati del terzo trimestre e fornisce le previsioni finanziarie. Le informazioni in Item 2.02 e nell'Esibizione 99.1 sono fornite, non depositate, e una copia del comunicato stampa è allegata come Esibizione 99.1.

OPKO Health (OPK) presentó un 8-K indicando que emitió un comunicado de prensa con los aspectos operativos y financieros para el trimestre terminado al 30 de septiembre de 2025. El comunicado también explica cómo acceder a la llamada de conferencia de la empresa que cubre los resultados del tercer trimestre y proporciona orientación financiera. La información en el Item 2.02 y en el Anexo 99.1 se está proporcionando, no presentado, y se adjunta una copia del comunicado de prensa como Anexo 99.1.

OPKO Health (OPK)가 8-K를 제출했습니다 분기말 2025년 9월 30일에 대한 운영 및 재무 하이라이트가 담긴 보도자료를 발행했다고 명시했습니다. 또한 보도자료는 회사의 3분기 실적 발표 컨퍼런스 콜에 접속하는 방법과 재무 전망에 대해 설명합니다. Item 2.02 및 Exhibit 99.1의 정보는 제출되는 것이지 기재되는 것이 아니며, 보도자료의 사본은 Exhibit 99.1로 첨부되어 있습니다.

OPKO Health (OPK) a fourni un formulaire 8-K indiquant qu'il a publié un communiqué de presse présentant les points saillants opérationnels et financiers pour le trimestre se terminant le 30 septembre 2025. Le communiqué explique également comment accéder à la conférence téléphonique de l'entreprise couvrant les résultats du troisième trimestre et fournit des prévisions financières. Les informations contenues dans l'Item 2.02 et l'Exhibit 99.1 sont fournies, et non déposées, et une copie du communiqué de presse est jointe en tant qu'Exhibit 99.1.

OPKO Health (OPK) hat eine 8-K vorgelegt, in der mitgeteilt wird, dass ein Pressemitteilung mit operativen und finanziellen Highlights für das Quartal zum 30. September 2025 veröffentlicht wurde. Die Mitteilung erläutert auch, wie man die Telefonkonferenz des Unternehmens zu den Ergebnissen des dritten Quartals zugänglich macht, und gibt finanzielle Leitlinien an. Die Informationen in Item 2.02 und Exhibit 99.1 werden als vorgelegt, nicht eingereicht, und eine Kopie der Pressemitteilung ist als Exhibit 99.1 beigefügt.

قدمت OPKO Health (OPK) نموذج 8-K تفيد أنها أصدرت بياناً صحفياً يبرز النقاط التشغيلية والمالية للربع المنتهي في 30 سبتمبر 2025. كما يشرح البيان كيفية الوصول إلى مكالمة المؤتمر الخاصة بالشركة التي تغطي نتائج الربع الثالث ويقدم توجيهات مالية. المعلومات الواردة في البند 2.02 والمعرض 99.1 يتم تقديمها، وليست مُقدمة للتسجيل، ونُسخة من البيان الصحفي مرفقة كالمعرض 99.1.

OPKO Health (OPK) 已提交一份8-K,声明其已发布一份包含截至2025年9月30日的季度运营和财务要点的新闻稿。该新闻稿还说明如何获取公司覆盖第三季度业绩的电话会议,并提供财务指引。信息在项目2.02和附件99.1中将被提交,不是备案,新闻稿的副本作为附件99.1附上。

false000094480900009448092025-10-292025-10-29

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 29, 2025

 

 

OPKO Health, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-33528

75-2402409

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

4400 Biscayne Blvd.

 

Miami, Florida

 

33137

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 305 575-4100

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock

 

OPK

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 2.02 Results of Operations and Financial Condition.

On October 29, 2025, OPKO Health, Inc. (the “Company”) issued a press release announcing operating and financial highlights for the quarter ended September 30, 2025. The press release also contains information on how to access the conference call the Company is hosting to provide a business update and discuss its financial and operating results for the third quarter ended September 30, 2025, as well as provide financial guidance. A copy of the press release is attached hereto as Exhibit 99.1.

The information included herein and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 as amended or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

 

(d)

Exhibits

Exhibit

No.

Description

99.1

Press Release of the Company dated October 29, 2025

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OPKO Health, Inc.

By:

/s/ Adam Logal

Date: October 29, 2025

Name:

Adam Logal

Title:

Senior Vice President, Chief Financial Officer

 

 

 


FAQ

What did OPKO Health (OPK) announce in this 8-K?

It issued a press release with operating and financial highlights for the quarter ended September 30, 2025.

Which SEC item does this relate to for OPK?

It relates to Item 2.02 (Results of Operations and Financial Condition).

When was the press release issued by OPKO Health?

The company announced the press release on October 29, 2025.

Does the announcement include conference call details?

Yes. The press release includes information on how to access the conference call covering third-quarter results.

Does OPKO provide financial guidance in this update?

Yes. The press release states the company will provide financial guidance.

Is the information considered filed or furnished?

The information in Item 2.02 and Exhibit 99.1 is furnished, not filed.

What exhibits are included with the 8-K?

Exhibit 99.1 is the press release; Exhibit 104 is the Cover Page Interactive Data File.
Opko Health

NASDAQ:OPK

OPK Rankings

OPK Latest News

OPK Latest SEC Filings

OPK Stock Data

1.12B
396.07M
46.77%
26.32%
4.09%
Diagnostics & Research
Pharmaceutical Preparations
Link
United States
MIAMI